Wall Street closes at a record for the first time since end of January
Heartflow, Inc. (HTFL) Chief Executive Officer John C.M. Farquhar sold 22,562 shares of common stock on April 10, 2026, for $26.72, totaling $602,856. The stock has since risen to $29.05, gaining over 8% in the past week.
Following the transaction, Farquhar directly owns 549,163 shares of Heartflow, Inc. The sale was executed under a pre-arranged Rule 10b5-1 trading plan adopted on September 12, 2025.According to InvestingPro analysis, HTFL appears overvalued at current levels and ranks among the most overvalued stocks. The company, valued at $2.31 billion, reports its next earnings on May 7, 2026.
In other recent news, Heartflow Inc. announced its fourth-quarter results, which surpassed expectations across all metrics, according to Piper Sandler. The company has also provided guidance for 2026. In legal developments, Heartflow has filed a patent infringement lawsuit against Cleerly Inc., alleging unauthorized use of its patented technology related to Ischemia, Plaque Analysis, and Compare products. The lawsuit, filed in the United States District Court for the Eastern District of Texas, seeks permanent injunctive relief and damages.
Analysts have responded to these developments with Canaccord and Stifel both reiterating their Buy ratings on Heartflow, setting price targets at $43.00 and $40.00, respectively. Canaccord’s note came in light of the intellectual property suit, while Stifel’s reaffirmation was influenced by the company’s clinical data strength and recent investor meetings. These analyst ratings suggest continued confidence in Heartflow’s market position despite the ongoing legal battle. Piper Sandler also maintained an Overweight rating with a $38.00 price target following the strong quarterly performance. These recent developments highlight a period of significant activity for Heartflow, encompassing both financial achievements and legal challenges.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.